Table 1.
Participant characteristics by treatment group
| No. of Patients (%) | |||||
|---|---|---|---|---|---|
| Characteristic | Overall | Chemo | No Chemo | Control | p-value |
| (n = 490) | (n = 160) | (n = 168) | (n = 162) | ||
| Age, M (SD) [n = 489] | 72.6 (6.0) | 70.9 (5.1) | 74.6 (5.9) | 72.1 (6.4) | <.001 |
| Race | |||||
| White | 415 (85%) | 129 (81%) | 141 (84%) | 145 (90%) | .282 |
| Black | 37 (8%) | 16 (10%) | 15 (9%) | 6 (4%) | |
| Asian/PI | 17 (3%) | 8 (5%) | 5 (3%) | 4 (2%) | |
| Other | 14 (3%) | 5 (3%) | 5 (3%) | 4 (2%) | |
| Missing | 7 (1%) | 2 (1%) | 2 (1%) | 3 (2%) | |
| Ethnicity | |||||
| Hispanic | 49 (10%) | 18 (11%) | 12 (7%) | 19 (12%) | .310 |
| Non-Hispanic | 432 (88%) | 138 (86%) | 153 (91%) | 141 (87%) | |
| Missing | 9 (2%) | 4 (3%) | 3 (2%) | 2 (1%) | |
| Education | |||||
| Less than college | 196 (40%) | 67 (42%) | 71 (42%) | 58 (36%) | .382 |
| College or more | 292 (60%) | 92 (58%) | 96 (57%) | 104 (64%) | |
| Missing | 2 (0%) | 1 (1%) | 1 (1%) | 0 (0%) | |
| WRAT, M (SD) [n = 487] | 63.1 (5.5) | 62.4 (6.5) | 63.4 (5.1) | 63.5 (4.6) | .137 |
| Employment | |||||
| Employed FT | 40 (8%) | 20 (13%) | 8 (5%) | 12 (7%) | .065 |
| Employed PT | 48 (10%) | 13 (8%) | 13 (8%) | 22 (14%) | |
| Unemployed | 23 (5%) | 5 (3%) | 9 (5%) | 9 (6%) | |
| Retired | 351 (72%) | 111 (69%) | 126 (75%) | 114 (70%) | |
| Missing | 28 (6%) | 11 (7%) | 12 (7%) | 5 (3%) | |
| Marital Status | |||||
| Married/DP | 341 (70%) | 104 (65%) | 128 (76%) | 109 (67%) | .246 |
| Widowed | 78 (16%) | 29 (18%) | 18 (11%) | 31 (19%) | |
| Divorced | 12 (2%) | 6 (4%) | 3 (2%) | 3 (2%) | |
| Single | 54 (11%) | 18 (11%) | 17 (10%) | 19 (12%) | |
| Missing | 5 (1%) | 3 (2%) | 2 (1%) | 0 (0%) | |
| Smoking Hx | |||||
| Yes | 224 (46%) | 85 (53%) | 74 (44%) | 65 (40%) | .049 |
| No | 264 (54%) | 74 (46%) | 93 (55%) | 97 (60%) | |
| Missing | 2 (0%) | 1 (1%) | 1 (1%) | 0 (0%) | |
| BMI, M (SD) [n = 480] | 27.4 (5.4) | 27.8 (5.8) | 27.4 (4.8) | 27.1 (5.5) | .515 |
| Frailty | |||||
| Robust | 336 (69%) | 103 (64%) | 109 (65%) | 124 (77%) | .125 |
| Pre-frail | 118 (24%) | 42 (26%) | 45 (27%) | 31 (19%) | |
| Frail | 34 (7%) | 14 (9%) | 13 (8%) | 7 (4%) | |
| Missing | 2 (<1%) | 1 (1%) | 1 (1%) | 0 (0%) | |
| Comorbidity Count, M (SD) | 2.1 (1.5) | 2.2 (1.6) | 2.3 (1.5) | 1.7 (1.4) | .001 |
| Endocrine Therapy | |||||
| Ever (n = 314) | 234 (75%) | 110 (72%) | 124 (77%) | NA | .298 |
| At Assessment 1 (n = 319) | 80 (25%) | 52 (34%) | 28 (17%) | NA | <.001 |
| Cancer Characteristics | |||||
| ER Positive (n = 297) | 237 (80%) | 111 (73%) | 126 (88%) | NA | .001 |
| PR Positive (n = 292) | 190 (65%) | 84 (55%) | 106 (76%) | NA | <.001 |
| HER2 (FISH) Positive (n = 266) | 32 (12%) | 25 (17%) | 7 (6%) | NA | .006 |
| Tumor size (cm), M (SD) | 1.7 (1.4) | 2.2 (1.5) | 1.2 (1.2) | NA | <.001 |
| Years since diagnosis, M (SD) | 8.0 (2.7) | 8.1 (2.7) | 8.0 (2.6) | NA | .574 |
| Site | |||||
| COH | 245 (50%) | 79 (49%) | 81 (48%) | 85 (52%) | .728 |
| MSK | 245 (50%) | 81 (51%) | 87 (52%) | 77 (48%) | |
| Baseline Psych [n = 488] | |||||
| FSI Disruption, M (SD) | 8.1 (11.0) | 9.5 (12.4) | 8.9 (10.8) | 5.9 (9.3) | .008 |
| STAI State Sum, M (SD) | 25.8 (7.3) | 26.8 (8.3) | 25.5 (6.9) | 25.0 (6.6) | .076 |
| CESD Sum, M (SD) | 6.8 (7.1) | 7.9 (8.8) | 6.6 (6.1) | 5.9 (5.9) | .043 |
| CESD, Meets Criteria | 45 (9%) | 21 (13%) | 15 (9%) | 9 (6%) | .060 |
| PAOFI Total, M (SD) | 25.2 (18.0) | 29.2 (21.8) | 23.7 (14.9) | 22.9 (16.1) | .003 |